The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 6, 2016, Pages 780-802

  Magerl, M ^a   Altrichter, S ^a   Borzova, E ^b   Gimenez Arnau A ^d   Grattan, C E H ^c   Lawlor, F ^c   Mathelier Fusade, P ^e   Meshkova, R Y ^f   Zuberbier, T ^a   Metz, M ^a   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Psychological Institute of Russian Education Academy   (Russian Federation)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HÔPITAL TENON   (France)

^f Klinika Medicinskoy Immunologii i Allergologii   (Russian Federation)

Author keywords

cholinergic urticaria; chronic inducible urticaria; physical urticaria

Indexed keywords

CYCLOSPORIN; OMALIZUMAB;

ANGIONEUROTIC EDEMA; AQUAGENIC URTICARIA; ARTICLE; CHOLINERGIC URTICARIA; CHRONIC INDUCIBLE URTICARIA; CHRONIC URTICARIA; COLD URTICARIA; CONSENSUS; CONTACT URTICARIA; DELAYED PRESSURE URTICARIA; DERMOGRAPHISM; DIAGNOSTIC TEST; HEAT URTICARIA; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PROVOCATION TEST; SOLAR URTICARIA; VIBRATORY ANGIOEDEMA; CHRONIC DISEASE; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; PRACTICE GUIDELINE; URTICARIA;

CHRONIC DISEASE; DIAGNOSTIC TESTS, ROUTINE; DISEASE MANAGEMENT; HUMANS; PRACTICE GUIDELINES AS TOPIC; URTICARIA;

EID: 84962909761     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12884     Document Type: Article

References (155)

1. Magerl M, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, et al., The definition and diagnostic testing of physical and cholinergic urticarias-EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64: 1715-1721.
2. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al., The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868-887.
3. Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S,. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol 2015; 115: 306-311.
4. Weldon D,. Quality of life in patients with urticaria and angioedema: assessing burden of disease. Allergy Asthma Proc 2014; 35: 4-9.
5. Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K,. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013; 68: 816-819.
6. Leigh IM, Ramsay CA, Calnan CD,. Cold urticaria-'desensitisation'. Trans St Johns Hosp Dermatol Soc 1974; 60: 40-42.
7. Black AK, Sibbald RG, Greaves MW,. Cold urticaria treated by induction of tolerance. Lancet 1979; 2: 964.
8. Leigh IM, Ramsay CA,. Localized heat urticaria treated by inducing tolerance to heat. Br J Dermatol 1975; 92: 191-194.
9. Ramsay CA,. Solar urticaria treatment by inducing tolerance to artificial radiation and natural light. Arch Dermatol 1977; 113: 1222-1225.
10. Breathnach SM, Allen R, Ward AM, Greaves MW,. Symptomatic dermographism: natural history, clinical features laboratory investigations and response to therapy. Clin Exp Dermatol 1983; 8: 463-476.
11. Dice JP,. Physical urticaria. Immunol Allergy Clin North Am 2004; 24: 225-246.
12. Duke WW,. Urticaria caused specifically by the action of physical agents: (light, cold, heat, freezing, burns, mechanical irritation, and physical and mental exertion). J Am Med Assoc 1924; 83: 3-9.
13. Bettley FR,. A device for the measurement of factitious urticaria. J Invest Dermatol 1962; 39: 1.
14. Schoepke N, Abajian M, Church MK, Magerl M,. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol 2015; 40: 399-403.
15. Magerl M, Schmolke J, Metz M, Zuberbier T, Siebenhaar F, Maurer M,. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol 2009; 34: e137-e140.
16. Sharpe GR, Shuster S,. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol 1993; 129: 580-583.
17. Krause K, Ardelean E, Kessler B, Magerl M, Metz M, Siebenhaar F, et al., Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010; 65: 1494-1495.
18. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al., Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154: 177-180.
19. Toda S, Takahagi S, Mihara S, Hide M,. Six cases of antihistamine-resistant dermographic urticaria treated with oral ciclosporin. Allergol Int 2011; 60: 547-550.
20. Borzova E, Rutherford A, Konstantinou GN, Leslie KS, Grattan CE,. Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. J Am Acad Dermatol 2008; 59: 752-757.
21. Adamski H, Viguier M,. Solar urticaria. Ann Dermatol Venereol 2012; 139: 324-328.
22. Hannuksela M, Kokkonen EL., Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol 1985; 65: 449-450.
23. Johnsson M, Falk ES, Volden G,. UVB treatment of factitious urticaria. Photodermatol 1987; 4: 302-304.
24. Logan RA, O'Brien TJ, Greaves MW,. The effect of psoralen photochemotherapy (PUVA) on symptomatic dermographism. Clin Exp Dermatol 1989; 14: 25-28.
25. Mathelier-Fusade P, Leynadier F,. Cold urticaria. Ann Dermatol Venereol 1994; 121: 429-433.
26. Wanderer AA,. An 'allergy' to cold. Hosp Pract 1979; 14: 136-137.
27. Möller A, Henning M, Zuberbier T, Czarnetzki-Henz BM,. Epidemiology and clinical aspects of cold urticaria. Hautarzt 1996; 47: 510-514.
28. Neittaanmaki H,. Cold urticaria. Clinical findings in 220 patients. J Am Acad Dermatol 1985; 13: 636-644.
29. Wanderer AA,. Essential acquired cold urticaria. J Allergy Clin Immunol 1990; 85: 531-532.
30. Krause K, Zuberbier T, Maurer M,. Modern approaches to the diagnosis and treatment of cold contact urticaria. Curr Allergy Asthma Rep 2010; 10: 243-249.
31. Hochstadter EF, Ben-Shoshan M,. Cold-induced urticaria: challenges in diagnosis and management. BMJ Case Rep 2013; doi: 10.1136/bcr-2013-010441
32. Wanderer AA, Grandel KE, Wasserman SI, Farr RS,. Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria. J Allergy Clin Immunol 1986; 78: 417-423.
33. Gimenez-Arnau A, Serra-Baldrich E, Camarasa JG,. Chronic aquagenic urticaria. Acta Derm Venereol 1992; 72: 389.
34. Magerl M, Abajian M, Krause K, Altrichter S, Siebenhaar F, Church MK,. An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. J Eur Acad Dermatol Venereol 2015; 29: 2043-2045.
35. Siebenhaar F, Staubach P, Metz M, Magerl M, Jung J, Maurer M,. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol 2004; 114: 1224-1225.
36. Koeppel MC, Bertrand S, Abitan R, Signoret R, Sayag J,. Urticaria caused by cold. 104 cases. Ann Dermatol Venereol 1996; 123: 627-632.
37. Mathelier-Fusade P, Aissaoui M, Bakhos D, Chabane MH, Leynadier F,. Clinical predictive factors of severity in cold urticaria. Arch Dermatol 1998; 134: 106-107.
38. Mlynek A, Magerl M, Siebenhaar F, Weller K, Vieira Dos Santos R, Zuberbier T, et al., Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol 2010; 162: 198-200.
39. Illig L,. Positive side-effects of antibiotic and antimicrobial drugs in therapy (author's transl). Infection 1979; 7 (Suppl. 6): 584-588.
40. Magerl M, Schmolke J, Siebenhaar F, Zuberbier T, Metz M, Maurer M,. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy 2007; 62: 1465-1468.
41. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, Maurer M,. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010; 104: 86-92.
42. Weinstein ME, Wolff AH, Bielory L,. Efficacy and tolerability of second- and third-generation antihistamines in the treatment of acquired cold urticaria: a meta-analysis. Ann Allergy Asthma Immunol 2010; 104: 518-522.
43. Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, et al., Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol 2016; 96: 56-59.
44. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M,. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921-928.
45. Magerl M, Pisarevskaja D, Staubach P, Martus P, Church MK, Maurer M,. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. Br J Dermatol 2012; 166: 1095-1099.
46. Martinez-Escala ME, Curto-Barredo L, Carnero L, Pujol RM, Gimenez-Arnau AM,. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol 2015; 95: 278-282.
47. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M,. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123: 672-679.
48. Boyce JA,. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117: 1415-1418.
49. Brodska P, Schmid-Grendelmeier P,. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol 2012; 4: 275-280.
50. Le Moing A, Becourt C, Pape E, Dejobert Y, Delaporte E, Staumont-Salle D,. Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases. J Am Acad Dermatol 2013; 69: e99-e101.
51. Kring Tannert L, Stahl SP, Bjerremann JL, Maurer M, Bindslev-Jensen C,. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology 2012; 224: 101-105.
52. von Mackensen YA, Sticherling M,. Cold urticaria: tolerance induction with cold baths. Br J Dermatol 2007; 157: 835-836.
53. Bodar EJ, Simon A, de Visser M, van der Meer JW,. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med 2009; 67: 302-305.
54. Gualdi G, Monari P, Rossi MT, Crotti S, Calzavara-Pinton PG,. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. Br J Dermatol 2012; 166: 1373-1374.
55. Chang A, Zic JA,. Localized heat urticaria. J Am Acad Dermatol 1999; 41: 354-356.
56. Koh YI, Choi IS, Lee SH, Lee JB, Park CH, Hong SN,. Localized heat urticaria associated with mast cell and eosinophil degranulation. J Allergy Clin Immunol 2002; 109: 714-715.
57. Irwin RB, Lieberman P, Friedman MM, Kaliner M, Kaplan R, Bale G, et al., Mediator release in local heat urticaria: protection with combined H1 and H2 antagonists. J Allergy Clin Immunol 1985; 76: 35-39.
58. Tomi NS, Schuster C, Bechara F, Hoffmann K, Kränke B,. Localized heat urticaria in a child. J Eur Acad Dermatol Venereol 2008; 22: 384-386.
59. Bullerkotte U, Wieczorek D, Kapp A, Wedi B,. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 2010; 65: 931-932.
60. Carballada F, Nunez R, Martin-Lazaro J, Juarez Y, Castineira I, Fernandez L, et al., Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergol Clin Immunol 2013; 23: 519-521.
61. Lawlor F, Black AK,. Delayed pressure urticaria. Immunol Allergy Clin North Am 2004; 24: 247-258.
62. Lawlor F, Black AK, Ward AM, Morris R, Greaves MW,. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989; 120: 403-408.
63. Ryan TJ, Shim-Young N, Turk JL,. Delayed pressure urticaria. Br J Dermatol 1968; 80: 485-490.
64. Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW,. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Dermatol 1993; 29: 954-958.
65. Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Vacca A,. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006; 155: 1279-1282.
66. Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A,. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 2003; 112: 212-213.
67. Berkun Y, Shalit M,. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55: 203-204.
68. Bindslev-Jensen C, Skov PS,. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010; 65: 138-139.
69. Rodriguez-Rodriguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Alvarez-Mon M,. Successful treatment of severe delayed pressure angio-oedema with omalizumab. Allergol Immunopathol (Madr) 2014; 42: 78-80.
70. Grundmann SA, Kiefer S, Luger TA, Brehler R,. Delayed pressure urticaria-dapsone heading for first-line therapy? J Dtsch Dermatol Ges 2011; 9: 908-912.
71. Engler RJ, Squire E, Benson P,. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995; 74: 155-159.
72. Swerlick RA, Puhar N,. Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients. Dermatol Ther 2015; 28: 318-322.
73. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M,. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007; 119: 752-754.
74. Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, Gregoriou S, Makris M, Boucher W, et al., Theophylline as "add-on" therapy in patients with delayed pressure urticaria: a prospective self-controlled study. Int J Immunopathol Pharmacol 2005; 18: 595-602.
75. Chong WS, Khoo SW,. Solar urticaria in Singapore: an uncommon photodermatosis seen in a tertiary dermatology center over a 10-year period. Photodermatol Photoimmunol Photomed 2004; 20: 101-104.
76. Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M,. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 1563-1565.
77. Bilsland D, Ferguson J,. A comparison of cetirizine and terfenadine in the management of solar urticaria. Photodermatol Photoimmunol Photomed 1991; 8: 62-64.
78. Masuoka E, Fukunaga A, Kishigami K, Jimbo H, Nishioka M, Uchimura Y, et al., Successful and long-lasting treatment of solar urticaria with ultraviolet A rush hardening therapy. Br J Dermatol 2012; 167: 198-201.
79. Wolf R, Herzinger T, Grahovac M, Prinz JC,. Solar urticaria: long-term rush hardening by inhibition spectrum narrow-band UVB 311 nm. Clin Exp Dermatol 2013; 38: 446-447.
80. Baliu-Pique C, Aguilera PP,. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2016; 30: 704-706.
81. Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD,. Successful omalizumab treatment of severe solar urticaria in a 6-year old child. Pediatr Allergy Immunol 2015; 26: 588-590.
82. Correia I, Silva J, Filipe P, Gomes M,. Solar urticaria treated successfully with intravenous high-dose immunoglobulin: a case report. Photodermatol Photoimmunol Photomed 2008; 24: 330-331.
83. Hughes R, Cusack C, Murphy GM, Kirby B,. Solar urticaria successfully treated with intravenous immunoglobulin. Clin Exp Dermatol 2009; 34: e660-e662.
84. Adamski H, Bedane C, Bonnevalle A, Thomas P, Peyron JL, Rouchouse B, et al., Solar urticaria treated with intravenous immunoglobulins. J Am Acad Dermatol 2011; 65: 336-340.
85. Aubin F, Porcher R, Jeanmougin M, Leonard F, Bedane C, Moreau A, et al., Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study. J Am Acad Dermatol 2014; 71: 948-953.
86. Edstrom DW, Ros AM,. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed 1997; 13: 61-63.
87. Duchini G, Baumler W, Bircher AJ, Scherer K,. Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 2011; 27: 336-337.
88. Llamas-Velasco M, Argila DD, Eguren C, Garcia-Martin P, Ibanes S, Garcia-Diez A,. Solar urticaria unresponsive to intravenous immunoglobulins. Photodermatol Photoimmunol Photomed 2011; 27: 53-54.
89. Müller S, Schempp CM, Jakob T,. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol 2016; 30: 524-525.
90. Hurabielle C, Bedane C, Avenel-Audran M, Adamski H, Aubin F, Jeanmougin M, et al., No Major effect of cyclosporine a in patients with severe solar urticaria: a french retrospective case series. Acta Derm Venereol 2015; 95: 1030-1031.
91. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE,. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. Br J Dermatol 2011; 164: 407-414.
92. Lawlor F, Black AK, Breathnach AS, Greaves MW,. Vibratory angioedema: lesion induction, clinical features, laboratory and ultrastructural findings and response to therapy. Br J Dermatol 1989; 120: 93-99.
93. Mathelier-Fusade P, Vermeulen C, Leynadier F,. Vibratory angioedema. Ann Dermatol Venereol 2001; 128: 750-752.
94. Keahey TM, Indrisano J, Lavker RM, Kaliner MA,. Delayed vibratory angioedema: insights into pathophysiologic mechanisms. J Allergy Clin Immunol 1987; 80: 831-838.
95. Pressler A, Grosber M, Halle M, Ring J, Brockow K,. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol 2013; 38: 151-153.
96. Czarnetzki BM,. Ketotifen in cholinergic urticaria. J Allergy Clin Immunol 1990; 86: 138-139.
97. Illig L,. On the pathogenesis of cholinergic urticaria. I. Clinical observations and histological studies. Arch Klin Exp Dermatol 1967; 229: 231-247.
98. Illig L, Heinicke A,. On the pathogenesis of cholinergic urticaria. II. Studies on the relationships of cholinergic urticaria to sweat secretions with the help of various cholinomimetics. Arch Klin Exp Dermatol 1967; 229: 285-299.
99. Illig L, Heinicke A,. On the pathogenesis of cholinergic urticaria. 3. The influence of sweat secretion inhibition on cholinergic urticaria. Arch Klin Exp Dermatol 1967; 229: 345-359.
100. Illig L, Heinicke A,. On the pathogenesis of cholinergic urticaria. IV. On the problem of a true antigen-antibody reaction. Arch Klin Exp Dermatol 1967; 229: 360-371.
101. Illig L, Heinicke A,. Pathogenesis of cholinergic urticaria. V. The pharmacologic reactivity of the Prausnitz-Kustner reaction and the origin of the antigen. Arch Klin Exp Dermatol 1967; 230: 34-47.
102. Montgomery SL,. Cholinergic urticaria and exercise-induced anaphylaxis. Curr Sports Med Rep 2015; 14: 61-63.
103. Altrichter S, Salow J, Ardelean E, Church MK, Werner A, Maurer M,. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci 2014; 75: 88-93.
104. Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM,. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol 1995; 75: 147-149.
105. Zuberbier T, Munzberger C, Haustein U, Trippas E, Burtin B, Mariz SD, et al., Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996; 193: 324-327.
106. Metz M, Bergmann P, Zuberbier T, Maurer M,. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 247-249.
107. Kutlu A, Tanoglu A, Ozturk S,. Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints. Chin Med J (Engl) 2015; 128: 1559-1560.
108. Ujiie H, Shimizu T, Natsuga K, Arita K, Tomizawa K, Shimizu H,. Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines. Clin Exp Dermatol 2006; 31: 588-589.
109. Altrichter S, Wosny K, Maurer M,. Successful treatment of cholinergic urticaria with methantheliniumbromide. J Dermatol 2015; 42: 422-424.
110. Feinberg JH, Toner CB,. Successful treatment of disabling cholinergic urticaria. Mil Med 2008; 173: 217-220.
111. Sheraz A, Halpern S,. Cholinergic urticaria responding to botulinum toxin injection for axillary hyperhidrosis. Br J Dermatol 2013; 168: 1369-1370.
112. Kozaru T, Fukunaga A, Taguchi K, Ogura K, Nagano T, Oka M, et al., Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int 2011; 60: 277-281.
113. Nakamizo S, Egawa G, Miyachi Y, Kabashima K,. Cholinergic urticaria: pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol 2012; 26: 114-116.
114. Berth-Jones J, Graham-Brown RA,. Cholinergic pruritus, erythema and urticaria: a disease spectrum responding to danazol. Br J Dermatol 1989; 121: 235-237.
115. La Shell MS, England RW,. Severe refractory cholinergic urticaria treated with danazol. J Drugs Dermatol 2006; 5: 664-667.
116. Wong E, Eftekhari N, Greaves MW, Ward AM,. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol 1987; 116: 553-556.
117. Pitarch G, Torrijos A, Martinez-Menchon T, Sanchez-Carazo JL, Fortea JM,. Familial aquagenic urticaria and Bernard-Soulier syndrome. Dermatology 2006; 212: 96-97.
118. Seize MB, Ianhez M, de SP, Rotta O, Cestari Sda C,. Familial aquagenic urticaria: report of two cases and literature review. An Bras Dermatol 2009; 84: 530-533.
119. Baptist AP, Baldwin JL,. Aquagenic urticaria with extracutaneous manifestations. Allergy Asthma Proc 2005; 26: 217-220.
120. Luong KV, Nguyen LT,. Aquagenic urticaria: report of a case and review of the literature. Ann Allergy Asthma Immunol 1998; 80: 483-485.
121. Czarnetzki BM, Breetholt KH, Traupe H,. Evidence that water acts as a carrier for an epidermal antigen in aquagenic urticaria. J Am Acad Dermatol 1986; 15: 623-627.
122. Yavuz ST, Sahiner UM, Tuncer A, Sackesen C,. Aquagenic urticaria in 2 adolescents. J Investig Allergol Clin Immunol 2010; 20: 624-625.
123. Park H, Kim HS, Yoo DS, Kim JW, Kim CW, Kim SS, et al., Aquagenic urticaria: a report of two cases. Ann Dermatol 2011; 23 (Suppl. 3): S371-S374.
124. Parker RK, Crowe MJ, Guin JD,. Aquagenic urticaria. Cutis 1992; 50: 283-284.
125. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A,. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol 1997; 36: 118-119.
126. Bayle P, Gadroy A, Messer L, Bazex J,. Localized aquagenic urticaria: efficacy of a barrier cream. Contact Dermatitis 2003; 49: 160-161.
127. Gimenez-Arnau AM, Maibach HI,. Contact Urticaria Syndrome. Boca Raton: CRC Press Taylor & Francis Group, 2015.
128. Lahti A,. Non-immunologic contact urticaria. Acta Derm Venereol Suppl (Stockh) 1980; 60: Suppl. 91: 1-49.
129. Lahti A,. Non-immunologic contact urticaria. Animal tests and their relevance. Acta Derm Venereol Suppl (Stockh) 1988; 135: 43-44.
130. Oliver F, Amon EU, Breathnach A, Francis DM, Sarathchandra P, Black AK, et al., Contact urticaria due to the common stinging nettle (Urtica dioica)-histological, ultrastructural and pharmacological studies. Clin Exp Dermatol 1991; 16: 1-7.
131. Fischer TW, Bauer A, Hipler UC, Elsner P,. Non-immunologic contact urticaria from chrysanthemum confirmed by the CAST method. Complement-activated (C5a) cellular antigen stimulation test. Contact Dermatitis 1999; 41: 293-295.
132. Zhai H, Zheng Y, Fautz R, Fuchs A, Maibach HI,. Reactions of non-immunologic contact urticaria on scalp, face, and back. Skin Res Technol 2012; 18: 436-441.
133. Wakelin SH,. Contact urticaria. Clin Exp Dermatol 2001; 26: 132-136.
134. Gimenez-Arnau A, Maurer M, De La Cuadra J, Maibach H,. Immediate contact skin reactions, an update of Contact Urticaria, Contact Urticaria Syndrome and Protein Contact Dermatitis-"A Never Ending Story". Eur J Dermatol 2010; 20: 552-562.
135. Gimenez-Arnau A,. Contact urticaria and the environment. Rev Environ Health 2014; 29: 207-215.
136. Wang CY, Maibach HI,. Immunologic contact urticaria-the human touch. Cutan Ocul Toxicol 2013; 32: 154-160.
137. Adisesh A, Robinson E, Nicholson PJ, Sen D, Wilkinson M,. U.K. standards of care for occupational contact dermatitis and occupational contact urticaria. Br J Dermatol 2013; 168: 1167-1175.
138. Bensefa-Colas L, Telle-Lamberton M, Faye S, Bourrain JL, Crepy MN, Lasfargues G, et al., Occupational contact urticaria: lessons from the French National Network for Occupational Disease Vigilance and Prevention (RNV3P). Br J Dermatol 2015; 173:: 1453-1461.
139. Johnson RF,. Letter: incidence of dermographism. Br Med J 1976; 1: 1533-1534.
140. Kirby JD, Matthews CN, James J, Duncan EH, Warin RP,. The incidence and other aspects of factitious wealing (dermographism). Br J Dermatol 1971; 85: 331-335.
141. Kontou-Fili K, Borici-Mazi R, Kapp A, Matjevic LJ, Mitchel FB,. Physical urticaria: classification and diagnostic guidelines. An EAACI position paper. Allergy 1997; 52: 504-513.
142. Abajian M, Mlynek A, Maurer M,. Physical urticaria. Curr Allergy Asthma Rep 2012; 12: 281-287.
143. Fleischer M, Grabbe J,. Physical urticaria. Hautarzt 2004; 55: 344-349.
144. Zuberbier T, Maurer M,. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007; 87: 196-205.
145. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Vieira Dos Santos R, et al., Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 2007; 32: 241-245.
146. Dover JS, Black AK, Ward AM, Greaves MW,. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 1988; 18: 1289-1298.
147. Sussman GL, Harvey RP, Schocket AL,. Delayed pressure urticaria. J Allergy Clin Immunol 1982; 70: 337-342.
148. Uetsu N, Miyauchi-Hashimoto H, Okamoto H, Horio T,. The clinical and photobiological characteristics of solar urticaria in 40 patients. Br J Dermatol 2000; 142: 32-38.
149. Eguino P, Lasa O, Gardeazabal J, Diaz-Perez JL,. Solar urticaria. Study of 20 cases. Actas Dermosifiliogr 2005; 96: 25-29.
150. Monfrecola G, Masturzo E, Riccardo AM, Balato F, Ayala F, Di Costanzo MP,. Solar urticaria: a report on 57 cases. Am J Contact Dermat 2000; 11: 89-94.
151. Godse K, Farooqui S, Nadkarni N, Patil S,. Prevalence of cholinergic urticaria in Indian adults. Indian Dermatol Online J 2013; 4: 62-63.
152. Silpa-archa N, Kulthanan K, Pinkaew S,. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol 2011; 25: 1194-1199.
153. Zuberbier T, Althaus C, Chantraine-Hess S, Czarnetzki BM,. Prevalence of cholinergic urticaria in young adults. J Am Acad Dermatol 1994; 31: 978-981.
154. Kim JE, Eun YS, Park YM, Park HJ, Yu DS, Kang H, et al., Clinical characteristics of cholinergic urticaria in Korea. Ann Dermatol 2014; 26: 189-194.
155. Moore-Robinson M, Warin RP,. Some clinical aspects of cholinergic urticaria. Br J Dermatol 1968; 80: 794-799.